About me
At Gilead Sciences, Laura leads the US reimbursement policy team focused on driving access to innovative medicines across Gilead’s oncology and virology portfolio, including reimbursement strategies for Kite Pharma, a leader in the development of novel CAR T therapies. Laura joined Gilead Sciences in Oct 2019 after almost 5 years at AstraZeneca where she held progressive roles on the US and Global teams focused on policy, government affairs, and patient advocacy as well as a decade in biopharma consulting. Ms. Okpala holds a Master of Public Health from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in Biology from Princeton University. She lives in Chevy Chase, DC and enjoys traveling, and trying local restaurants.
